Erbitux Launch Benefits From EGFR Screening, ImClone Says
This article was originally published in The Pink Sheet Daily
Executive Summary
Screening prospective patients for expression of epidermal growth factor receptor will positively affect Erbitux' launch, ImClone said April 27
You may also be interested in...
Erbitux Phase IV Studies Will Evaluate EGFR Expression As Patient Selection Criterion
Two of 13 total postmarketing commitments involve studying the efficacy of Erbitux in patients with EGFR-negative colorectal cancer. Other Phase IVs include a dose finding study in the pediatric population.
Bristol/ImClone's Erbitux Clears FDA
Erbitux is indicated in treatment of EGFR-expressing, metastatic colorectal carcinoma for use in combination with irinotecan or as monotherapy.
Able Unable To Reform On Its Own? Firm Seeks Consent Decree To Address Manufacturing Issues
“We are prepared to enter discussions toward a decree at FDA’s earliest convenience,” Able says in letter to FDA. Company is pursuing consent decree instead of responding to FDA Form 483 report citing manufacturing deficiencies. The letter follows CEO Maury’s resignation the previous day.